Bone Marrow Transplantation Using HLA-Matched Unrelated Donors for Patients Suffering from Severe Combined Immunodeficiency Eyal Grunebaum, MD, Chaim.

Slides:

Advertisements

Similar presentations

Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture John E. Wagner,

Advertisements

Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation

Stephanie J. Lee, Loretta A. Williams

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Building better therapy for children with acute lymphoblastic leukemia

Volume 18, Issue 1, Pages (January 2016)

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology.

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.

Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency by Ronald.

Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture John E. Wagner,

Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency Vy Hong-Diep Kim, MD, Brenda Reid,

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning Niraj.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency Justin Wahlstrom,

A History of Bone Marrow Transplantation

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Cardiac Chamber Hypertrophy following Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Sean R. Bulley, Lee Benson, Eyal Grunebaum,

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Stephanie J. Lee, Loretta A. Williams

Chronic graft-versus-host disease

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft- versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow.

Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young.

Late thymic deficiency after HLA-haploidentical hematopoietic stem cell transplantation for severe combined immunodeficiency Markus J. Ege, MD, Catharina.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Kasiani C. Myers, Stella M. Davies

Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion

Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Biology of Blood and Marrow Transplantation

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

R. Pfitzmann, MD, M. Hummel, MD, O. Grauhan, MD, P. Waurick, MD, R

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

Preface Hematology/Oncology Clinics

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Comparable Long-Term Survival after Bone Marrow versus Peripheral Blood Progenitor Cell Transplantation from Matched Unrelated Donors in Children with.

Primary cellular immunodeficiencies

Iron Disorders Hematology/Oncology Clinics

Mary Eapen Biology of Blood and Marrow Transplantation

Hematopoietic stem cell transplantation for CD3δ deficiency

Presentation transcript:

Bone Marrow Transplantation Using HLA-Matched Unrelated Donors for Patients Suffering from Severe Combined Immunodeficiency Eyal Grunebaum, MD, Chaim M. Roifman, MD, FRCPC, FCACB Hematology/Oncology Clinics Volume 25, Issue 1, Pages 63-73 (February 2011) DOI: 10.1016/j.hoc.2010.11.005 Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 1 Increase in registered bone marrow donors and registries. Number of countries that have bone marrow registries, number of registries, and number of donors (in millions) registered in 1986, 1996, and 2006. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 2 Survival of patients with SCID who received BMT from MUD or MMRD. Percentage of patients surviving after MUD or MMRD BMT. For patients who received multiple transplants, survival was calculated from the date of the last transplant. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 3 Engraftment of hematopoietic lineages after MUD BMT for SCID. The numbers of days required to achieve engraftment of neutrophils (absolute neutrophil count >500/μL), red blood cells (last red blood cells transfusion), and platelets (platelets >20,000/μL) after MUD BMT for patients with SCID at the Hospital for Sick Children, Toronto, Canada. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 4 Graft loss after MUD or MMRD BMT for SCID. Percentage of patients with SCID that lost donor lymphocyte engraftment after MUD or MMRD BMT. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 5 T-cell receptor repertoire after MUD or MMRD BMT for SCID. Percentage of patients with SCID that achieved normal T-cell repertoire, as determined by T-cell receptor variable beta chain expression, after MUD or MMRD BMT. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 6 Pneumonitis after MUD or MMRD BMT for SCID. Number of patients with SCID that suffered interstitial pneumonitis and died of interstitial pneumonitis after MUD or MMRD BMT. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions

Fig. 7 Acute graft versus host disease after MUD or MMRD BMT for SCID. Percentage of patients with SCID that suffered acute graft versus host disease or grade III and higher acute graft versus host disease after MUD or MMRD BMT. Hematology/Oncology Clinics 2011 25, 63-73DOI: (10.1016/j.hoc.2010.11.005) Copyright © 2011 Elsevier Inc. Terms and Conditions